Regenicin, Inc. (RGIN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Little Falls, NJ, United States. The current CEO is Randall E. McCoy.
RGIN has IPO date of 2009-11-16, 3 full-time employees, listed on the Other OTC, a market capitalization of $15.35K.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
